LORMETAZEPAM

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H12Cl2N2O2
Molecular Weight	335.185
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3

InChI

InChIKey=FJIKWRGCXUCUIG-UHFFFAOYSA-N

InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3

HIDE SMILES / InChI

Molecular Formula	C16H12Cl2N2O2
Molecular Weight	335.185
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://home.intekom.com/pharm/schering/noctamid.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1687574 https://www.ncbi.nlm.nih.gov/pubmed/6124982

Lormetazepam (or methyl-lorazepam), possesses hypnotic, anxiolytic, sedative and skeletal muscle relaxant properties. Lormetazepam is not approved for sale in the United States or Canada, though it is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several different manufacturers. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Lormetazepam binds to the benzodiazepine receptor which in turn enhances the effect of the GABAA receptor producing its therapeutic effects as well as adverse effects. Lormetazepam appears to be more selective in the type of benzodiazepine receptor it binds to showing a higher affinity for the omega 1 receptor which is responsible for sedation. Changes in electroencephalography can therefore be used to measure the sedative sleep promoting properties of lormetazepam.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1687574	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 108 Sources: http://home.intekom.com/pharm/schering/noctamid.html	Curative		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Instead of benzodiazepines. An antidepressant as sleep aid].	2001 Jan 18	11215344
Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research--limits and progress.	2001 Jul	11426882
Lormetazepam effects on daytime vigilance, psychomotor performance and simulated driving in young adult healthy volunteers.	2002 Jul	12139207
Musical hallucinations during a treatment with benzodiazepine.	2002 Oct	12420663
Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.	2002 Sep	12237787
The use of hypnosedative drugs in a university hospital setting.	2003 Jul-Aug	14635530
Residual effects of hypnotics: epidemiology and clinical implications.	2004	15089115
Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis.	2004 Jul	15252823
[The use of anxiolytic and hypnotic drugs in Spain (1995-2002)].	2004 May-Jun	15293958
Lormetazepam in depressive insomnia: new evidence of phase-response effects of benzodiazepines.	2004 Sep	15289705
Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.	2005 Jan	15763608
[Benzodiazepine and hiccup: three case reports].	2005 Jan-Feb	15929474
Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS.	2005 Jun 10	15944062
Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring.	2005 Oct	16025317
Quantification of benzodiazepines in whole blood and serum.	2006 Nov	16220317
Eszopiclone: its use in the treatment of insomnia.	2007 Aug	19300573
Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report.	2008 Jun 11	18547425
Clinical review: The impact of noise on patients' sleep and the effectiveness of noise reduction strategies in intensive care units.	2009	19344486
Analysis of six benzodiazepines in vitreous humor by high-performance liquid chromatography-photodiode-array detection.	2010 Nov	21073805

Patents

Sample Use Guides

In Vivo Use Guide

1 tablet Noctamid (lormetazepam) (1 mg) as a single dose. Elderly and debilitated patients take half a tablet (0,5 mg).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:26:14 UTC 2023` Edited by `admin` on `Fri Dec 15 15:26:14 UTC 2023`
Record UNII	GU56C842ZA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LORMETAZEPAM

Official Name

English

LORMETAZEPAM [USAN]

Common Name

English

7-Chloro-5-(O-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one

Common Name

English

LORMETAZEPAM [MART.]

Common Name

English

2H-1,4-BENZODIAZEPIN-2-ONE, 7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-1-METHYL-

Systematic Name

English

Lormetazepam [WHO-DD]

Common Name

English

7-CHLORO-5-(2-CHLOROPHENYL)-1,3-DIHYDRO-3-HYDROXY-1-METHYL-2H-1,4-BENZODIAZEPIN-2-ONE

Systematic Name

English

LORMETAZEPAM [MI]

Common Name

English

WY-4082

Code

English

LORMETAZEPAM [JAN]

Common Name

English

LORAMET

Brand Name

English

lormetazepam [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012